Rhythm Pharmaceuticals (RYTM) Share-based Compensation (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Share-based Compensation data on file, last reported at $8.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $75.3 million, a 135.86% increase from a year earlier, with the FY2025 full-year figure at $66.8 million, up 29.45% from the prior year.
• Share-based Compensation for Q1 2026 stood at $8.5 million, down from $19.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for RYTM reached as high as $28.7 million in Q2 2025 and fell as low as $4.6 million in Q1 2022.
• Historically, Share-based Compensation has averaged $10.5 million across 5 years, with a median of $8.6 million in 2023.
• Across the five-year window, Share-based Compensation fell 11.17% in 2022 and surged 177.49% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $5.3 million in 2022, then surged by 64.06% to $8.7 million in 2023, then gained by 21.7% to $10.6 million in 2024, then jumped by 82.51% to $19.3 million in 2025, then tumbled by 56.1% to $8.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $8.5 million in Q1 2026, $19.3 million in Q4 2025, and $18.8 million in Q3 2025.